Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Phase 1

Completed

Interventions: Biological: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
Biological: Standard Dose Trivalent Inactivated Flu Vaccine

Brief Summary: Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly different from adult stem cell transplant recipients receiving standard dose (SD) TIV.

* Specific Aim 1: To compare safety profile of high dose trivalent inactivated influenza vaccine to standard dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplant recipients.

Hypothesis 2: Adult stem cell transplant recipients who received the higher dose trivalent influenza vaccine will have a greater frequency of (at least a 4-fold) rise in antibody titers to influenza antigens compared to those who receive standard dose trivalent influenza vaccine.

* Specific Aim 2: To compare humoral immune responses of adult hematopoietic stem cell transplant recipients influenza virus antigens included in trivalent influenza vaccine after high dose or standard dose trivalent influenza vaccine.

Recruitment & Eligibility

Inclusion Criteria

Allogeneic hematopoietic stem cell transplant recipients who are >6 post-transplant
greater than or equal to 18 years of age
Available for duration of study
If patients are on immunosuppressive therapy for treatment of graft versus host disease (GVHD): only those on stable doses for at least 4 weeks or on tapering doses will be eligible.

Exclusion Criteria

History of hypersensitivity to previous influenza vaccination or hypersensitivity to eggs/egg protein
History of Guillain-Barre syndrome
Evidence of hematologic malignancy or disease relapse post-transplant (mixed chimerisms and molecular evidence of disease is permitted)
Non-allogeneic (e.g. autologous) hematopoietic SCT recipients
History of receiving 2011 - 2012 influenza vaccine
History of proven influenza disease after September 1, 2011.
Pregnant females
Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol
Have any condition that the investigator believes may interfere with successful completion of the study
Platelet count less than 50,000 cells/μL
History of known infection with HIV, Hepatitis B or Hepatitis C
History of known latex hypersensitivity

Arm && Interventions

Group	Intervention	Description
High-Dose Trivalent Inactivated Influenza Vaccine	High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)	Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
Standard dose Trivalent Inactivated Flu Vaccine	Standard Dose Trivalent Inactivated Flu Vaccine	Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.

Primary Outcome Measures

Name	Time	Method
Patients Experiencing at Least 1 Solicited Local and/or Systemic Adverse Event After High Dose (HD) Trivalent Influenza Vaccine (TIV) or Standard Dose (SD) Trivalent Influenza Vaccine in Adult Hematopoetic Stem Cell Transplant (SCT) Recipients	Day of TIV to 7 days after TIV	Patients were questioned about the following adverse events related to TIV: Local: pain, tenderness, swelling/induration, or erythema at injection site. Systemic: fatigue/malaise, headache, nausea, vomiting, body ache not at injection site, fever \>= 100.4 degrees Fahrenheit, or change in activity level.

Secondary Outcome Measures

Name	Time	Method
Patients Receiving HD or SD TIV With a 4-fold Rise in Hemagglutination Inhibition (HAI) Titers Relative to Baseline for Each of 3 Influenza Viruses	Before TIV and 28-42 days after TIV	Adult hematopoetic stem cell transplant recipients at least 6 months post-transplant receiving either HD or SD TIV who had blood drawn at pre-vaccination and at 28-42 days post-vaccination and who experienced a 4-fold rise in each of three post-vaccination influenza antibody titers, relative to their baseline titers. Trivalent vaccine is for the H1N1/H3N2/B influenzas. A 4-fold rise in type-specific antibody titer is considered adequate antibody response to the specific influenza virus